We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+49.89%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.26B
AUM Growth
+$210M
Cap. Flow
-$90.5M
Cap. Flow %
-7.19%
Top 10 Hldgs %
54.98%
Holding
68
New
14
Increased
7
Reduced
27
Closed
17

Top Buys

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$52.2M
2
PBYI icon
Puma Biotechnology
PBYI
+$33.5M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$32.1M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$28.5M
5
INCY icon
Incyte
INCY
+$24.9M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$56.1M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$26.6M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$25.7M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$25.1M
5
BKD icon
Brookdale Senior Living
BKD
+$23.9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.15%
2 Communication Services 1.37%
3 Consumer Staples 0.51%
4 Technology 0%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MODN
26
DELISTED
MODEL N, INC.
MODN
$17.2M 1.37%
1,550,959
-349,700
-18% -$4.1M
BOLD
27
DELISTED
Audentes Therapeutics, Inc
BOLD
$14.9M 1.19%
+916,626
New +$13.9M
NDRM
28
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$14.9M 1.18%
805,246
-16,199
-2% -$281K
SYRS
29
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$11.7M 0.93%
89,278
-5,340
-6% -$678K
CTMX icon
30
CytomX Therapeutics
CTMX
$725M
$11.2M 0.89%
714,692
-19,207
-3% -$232K
CRL icon
31
Charles River Laboratories
CRL
$10.5B
$10.6M 0.84%
127,106
-4,500
-3% -$377K
AZN icon
32
AstraZeneca
AZN
$263B
$9.47M 0.75%
+144,178
New +$9.42M
SPNC
33
DELISTED
Spectranetics Corp
SPNC
$8.4M 0.67%
334,741
-67,095
-17% -$1.57M
IRWD icon
34
Ironwood Pharmaceuticals
IRWD
$639M
$6.49M 0.52%
487,704
-40,893
-8% -$478K
WOOF
35
DELISTED
VCA Inc.
WOOF
$6.37M 0.51%
91,000
-3,200
-3% -$224K
ALXN
36
DELISTED
Alexion Pharmaceuticals
ALXN
$5.57M 0.44%
45,410
-156,990
-78% -$20.2M
ITCI
37
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.13M 0.41%
336,759
-634,806
-65% -$25.7M
NVTA
38
DELISTED
Invitae Corporation
NVTA
$4.47M 0.36%
510,369
-34,570
-6% -$291K
FATE icon
39
Fate Therapeutics
FATE
$301M
$4.45M 0.35%
1,425,158
-77,022
-5% -$187K
PRQR icon
40
ProQR Therapeutics
PRQR
$255M
$3.84M 0.31%
575,863
-5,775
-1% -$31.8K
BPMC
41
DELISTED
Blueprint Medicines
BPMC
$818K 0.07%
27,539
-814
-3% -$20.2K
AUPH icon
42
Aurinia Pharmaceuticals
AUPH
$1.97B
$565K 0.04%
187,610
+159,200
+560% +$429K
FBT icon
43
First Trust NYSE Arca Biotechnology Index Fund
FBT
$2.77B
$308K 0.02%
+3,090
New +$303K
UNH icon
44
UnitedHealth
UNH
$392B
$255K 0.02%
+1,820
New +$255K
HUM icon
45
Humana
HUM
$47.7B
$246K 0.02%
+1,390
New +$241K
DXCM icon
46
DexCom
DXCM
$27.6B
$216K 0.02%
+9,840
New +$219K
BIIB icon
47
Biogen
BIIB
$29.2B
$212K 0.02%
677
-552
-45% -$163K
AKAO
48
DELISTED
Achaogen Inc
AKAO
$155K 0.01%
+32,300
New +$129K
ADVM
49
DELISTED
Adverum Biotechnologies
ADVM
$91K 0.01%
2,224
– –
CSLT
50
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$43K ﹤0.01%
10,229
– –
1
2
3

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q3 2016 Portfolio in Review

As of Q3 2016, Redmile Group held 68 positions worth $1.26B, up 20% from $1.05B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Redmile Group withdrew a net $90.5M in Q3 2016, closing 17 positions and reducing 27 holdings. Its most notable exit was MEDIVATION, INC., an estimated $56.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 73% a quarter earlier, followed by Communication Services and Consumer Staples.

Against the trend, Redmile Group opened a new position in GW Pharmaceuticals Plc American Depositary Shares worth $72.5M.

  • Redmile Group's largest Q3 2016 buy was GW Pharmaceuticals Plc American Depositary Shares: 545,922 shares worth $72.5M.
  • Redmile Group added most to Incyte in Q3 2016, an estimated $24.9M increase.
  • Redmile Group's biggest Q3 2016 reduction was Intra-Cellular Therapies Inc., cutting an estimated $25.7M.
  • Redmile Group fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $56.1M.
  • Redmile Group's ten largest holdings make up 55% of its $1.26B portfolio in Q3 2016.
  • Redmile Group opened 14 new positions and closed 17 in Q3 2016.
  • Redmile Group's portfolio value rose 20% quarter-over-quarter to $1.26B.

Based on Redmile Group's 13F filing for Q3 2016, filed 15 Nov 2016.